CoreRx, Societal CDMO, and Bend Bioscience Merge Under Bend Bioscience Brand
CoreRx, Societal CDMO, and Bend Bioscience have announced a merger under the Bend Bioscience brand to create, they say, a unified, world-class CDMO combining the expertise and capabilities of the three companies to enhance their service offerings in pharmaceutical development and manufacturing. The newly consolidated entity plans to focus on innovative drug development solutions, providing a broad range of services from early-stage development to commercial-scale manufacturing.
The following article originally appeared in PR Newswire.
In a significant move, CoreRx, Societal CDMO, and Bend Bioscience have announced their unification under the Bend Bioscience brand. This merger brings together three highly respected organizations, each with a unique legacy and distinct strengths, to form a comprehensive contract development and manufacturing organization (CDMO) that offers an end-to-end suite of services.
The decision to adopt the Bend Bioscience name reflects the company's commitment to innovation, technical excellence and unmatched customer service; a reputation established by Bend Bioscience since its inception. However, this unification equally honors the rich legacies of CoreRx and Societal CDMO, whose contributions and expertise will be foundational to the new brand.
CoreRx has long been recognized for its innovation in formulation development, providing customized, cutting-edge solutions that address some of the most complex challenges in drug development. Their specialized knowledge in the creation of innovative drug delivery systems and complex formulations will continue to be a critical component of Bend Bioscience's expanded service offerings.
Societal CDMO provides deep expertise in scalable manufacturing and commercial production, with a proven track record of quality and reliability. Their robust capabilities in cGMP manufacturing, packaging, and supply chain management complement the scientific and technical strengths of both CoreRx and Bend Bioscience, allowing the newly combined organization to offer a fully integrated development-to-commercialization pathway for its clients.
"Bend Bioscience was chosen as the unified brand because it encapsulates the scientific excellence and innovative spirit that all three companies represent," said Owen Murray, CEO of Bend Bioscience. "This merger is not just about combining resources; it's about building on the strengths of CoreRx's advanced formulation development, Societal CDMO's respected manufacturing capabilities in the area of modified release, and Bend Bioscience's leadership in scientific research and technology. Together, we are creating a CDMO that offers unmatched value and service to our clients and their patients."
By coming together under the Bend Bioscience brand, the new organization is poised to leverage its combined expertise, enhance operational efficiencies, and deliver comprehensive, high-quality services that help bring life-saving therapies to market faster and more efficiently.
For more, please find the original story source here.
